Description
(AWP Alliance News) - Basilea Pharmaceutica AG outlined an asset-light partnering strategy centered on hospital anti-infectives, with Cresemba and Zevtera positioned as its two revenue-generating brands. Cresemba recorded USD 817 million in in-market sales for the July 2025 to June 2026 period, a 25% year-on-year increase, with the product marketed in 76 countries.
Zevtera's US launch through Innoviva Specialty Therapeutics was highlighted as building early ordering momentum, with US market exclusivity running until April 2034. The company also flagged late-stage pipeline priorities in fosmanogepix and ceftibuten-ledaborbactam, each cited with peak sales potential of about USD 1 billion and about USD 500 million, respectively. Basilea reported more than USD 440 million of non-dilutive R&D funding committed by BARDA and CARB-X, with about USD 165 million awarded.
https://docs.publicnow.com/76D99F30A8325DD76AD47BF17A81AE3096596D2A
Disclaimer: This news brief was created using generative artificial intelligence. Basilea Pharmaceutica AG published the original content used to generate this news brief on October 02, 2026, and is solely responsible for the information contained therein.
